Full-Time

Medical Writing Director

Deadline 5/15/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

Toronto, ON, Canada

Hybrid

Remote work options may be considered on a case-by-case basis.

Category
Content & Writing (1)
Requirements
  • A university/college degree in a scientific discipline is required.
  • An advanced degree (e.g., Masters, PhD, MD) is preferred.
Responsibilities
  • Assume overall accountability for decision-making within the organization or therapeutic area, ensuring alignment with strategic goals.
  • Proactively identify potential risks and develop strategies to mitigate them, enhancing project outcomes and minimizing obstacles.
  • Recognize and resolve complex problems related to the development and implementation of new service offerings and deliverables, working independently to find effective solutions.
  • Provide guidance to other writers on all types of clinical, regulatory, and safety documents, taking a proactive lead in content and scientific strategy with complete independence.
  • Represent the Medical Writing department with decision-making authority in the Research and Development organization, leading discussions with senior cross-functional colleagues and external partners to enhance coordination between departments.
  • Directly lead or set objectives for team projects and tasks, including leading program-level, submission, indication, and disease area writing teams independently.
  • Serve as a liaison between team members and senior leadership within a therapeutic area or sub-function, facilitating effective communication and collaboration.
  • Develop, implement, and drive the institutionalization of departmental process improvements and best practices in collaboration with relevant Communities of Practice and Business Process Owners, championing these initiatives to cross-functional team members.
  • Mentor, support, and coach staff at all levels on document planning, processes, and content, providing peer review as needed.
  • Maintain and disseminate knowledge of industry, company, and regulatory guidelines within relevant company systems.
  • Participate in industry standards working groups to represent Medical Writing and ensure alignment with best practices.
  • Act as the primary interface with the Compound Development Teams at the early stages of submission preparation and as a Medical Writing expert for the delivery of Johnson & Johnson Innovative Medicine marketing applications.
  • Bring scientific and regulatory submissions expertise to the clinical components of marketing applications, across all therapeutic areas.
  • Recognized as a subject matter expert responsible for submission strategy in support of multiple submissions across different therapeutic areas, starting with collaboration on the early draft label.
  • Develop/maintain submission training materials specific to clinical content, and submission document requirements/processes, training teams as needed; and promote optimized planning, execution, and delivery of submissions.
  • Support development of and team adherence to Submission Excellence best practices and drives consistency of departmental practices across Research and Development.
  • Lead early strategic submission discussions in collaboration with key stakeholders and senior leadership, focusing on clinical scientific content.
  • Hold the cross-functional team accountable for developing the clinical storyboard document, prioritizing and making decisions on activities that impact Medical Writing deliverables.
Desired Qualifications
  • A university/college degree in a scientific discipline is required. An advanced degree (e.g., Masters, PhD, MD) is preferred.
  • Minimum of 14 years of relevant pharmaceutical/scientific experience is required.
  • Minimum of 12 years of relevant clinical/medical writing experience is required.
  • Expert time management for self, direct reports (if applicable), and teams.
  • Ability to delegate responsibility to other medical writers.
  • Expert ability to lead and influence by example and stay focused (positive). Demonstrate integrity.
  • Expert ability to motivate and develop best in class talent pipeline.
  • Demonstrated ability to collaborate internally and develop effective partnerships with key business partners and customers.
  • Creates a positive Credo-based work environment for staff members.
  • Shows openness to new ideas and fosters organizational learning.
  • Excellent oral and written communication skills.
  • Attention to detail.
  • Strong decision-making skills, strategic thinking, agility, broad vision.
  • Experience with project management and process improvement.
  • Cross-Functional Collaboration
  • Developing Others
  • Inclusive Leadership
  • Leadership
  • Medical Affairs
  • Medical Communications
  • Performance Measurement
  • Quality Validation
  • Standard Operating Procedure (SOP)
  • Succession Planning
  • Tactical Planning
  • Business Writing
  • Clinical Research and Regulations
  • Clinical Trials Operations
  • Copy Editing
  • Industry Analysis

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hit $24.1 billion, up 9.9%, raising 2026 forecast to $100.8 billion.
  • Nipocalimab gains FDA Priority Review for autoimmune hemolytic anemia and myasthenia gravis efficacy.
  • Shockwave C2 Aero launches in US and Japan targeting 315 million calcified CAD patients.

What critics are saying

  • Stelara sales plunge 60% to $656 million in Q1 2026 post-patent expiration, creating $2.3 billion hole.
  • Icotyde stalls at 1,500 prescriptions, missing oncology targets by Q3 2026.
  • CAPLYTA faces Invega Sustenna competition, achieving under 10% adoption by mid-2027.

What makes Johnson & Johnson unique

  • J&J unites Innovative Medicine and MedTech under single brand since September 2023.
  • DARZALEX and TREMFYA dominate oncology and immunology with $57 billion pharma sales in 2024.
  • CARTO System leads electrophysiology for 30 years with AI-powered CARTOSOUND SONATA.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Johnson & Johnson who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.